A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

NCT03844256 | Recruiting Phase 1 DMC

• 1 other identifier: CA2099TT
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 3

Brief Summary

A multicenter Phase 1b/2, two stage, open label study of MMC/Capecitabine ChRT combined with nivolumab monotherapy or nivolumab and ipilimumab combination therapy in adult (\>18 years) subjects with non-metastatic muscle invasive bladder cancer that qualify for ChRT with curative intent.

Conditions

Urinary Bladder Cancer; Invasive Bladder Cancer

Keywords

Immunotherapy; Chemoradiotherapy; Nivolumab; Ipilimumab; bladder sparing treatment

Outcome Measures

Primary Outcomes (4)

• Toxicity scored with CTCAE v 4.03

  Toxicity scored with CTCAE v 4.03

  6 weeks after start of the combination therapy

• Incidence of dose limiting toxicity (DLT)

  6 weeks after start of combination therapy

• Disease free survival (DFS)

  5 years

• disease free survival-rate (DFS-rate)

  5 years

Secondary Outcomes (3)

• Overall survival

  5 years

• Overall survival rate

  5 years

• Response rate

  up to 5 years

Study Arms (3)

Regimen A

EXPERIMENTAL

Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses. All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.

Combination Product: nivolumab 480mg

Regimen B

EXPERIMENTAL

Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses. All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.

Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg

Regimen C

EXPERIMENTAL

Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses. All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.

Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg

Interventions

nivolumab 480mg COMBINATION_PRODUCT

Immuno-chemoradiotherapy

Also known as: mitomycin-c 12mg/m2 IV, capecitabine 750mg/m2, radiotherapy 40Gy in 20 fractions of 2Gy

Regimen A

nivolumab 3mg/kg, ipilimumab 1mg/kg COMBINATION_PRODUCT

Immuno-chemoradiotherapy

Also known as: mitomycin-c 12mg/m2 IV, capecitabine 750mg/m2, radiotherapy 40Gy in 20 fractions of 2Gy

Regimen B

nivolumab 1mg/kg, ipilimumab 3mg/kg COMBINATION_PRODUCT

Immuno-chemoradiotherapy

Also known as: mitomycin-c 12mg/m2 IV, capecitabine 750mg/m2, radiotherapy 40Gy in 20 fractions of 2Gy

Regimen C

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be willing and able to provide written informed consent for the trial.
• Be ≥ 18 years of age on day of signing informed consent.
• Wish to preserve their bladder function or be ineligible for cystectomy.
• Must have undergone transurethral biopsy of the bladder tumor, within 35 days of planned treatment commencement. The patient should have a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder.
• Must have undergone maximal transurethral resection of the bladder tumour, to an extent that is judged as safe by the urologist performing the resection, within 35 days of planned treatment commencement.
• Subjects with tumors of mixed urothelial/non-urothelial cell histology are allowed, but urothelial cell carcinoma must be the predominant histology (\>50%). Subjects with predominant or exclusively non-urothelial cell histology are not allowed.
• Have planned for chemoradiotherapy as definitive treatment.
• Have a performance status of 0 or 1 on the ECOG Performance Scale
• Have a bladder function that is accessible for cystoscopical follow up.
• Demonstrate adequate organ function. All screening labs should be performed within 28 days of registering the patient on the trial.
• Female participants of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Female participants of childbearing potential should be willing to one highly effective method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 month after the last dose of study medication Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year.
• Male participants should agree to use condoms starting with the first dose of study therapy through 7 month after the last dose of study therapy.
• Willing to consent to the use of their collected tumor specimen, blood and urine as detailed in the protocol for future scientific research including but not limited to DNA, RNA and protein based biomarker detection.

You may not qualify if:

• Has DPD deficiency.
• Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) urothelial cell carcinoma of the urothelium. Patients who have involvement of the prostatic urethra with urothelial cell cancer may be included if the location can be safely incorporated in the radiation field.
• Extensive or multifocal bladder carcinoma in situ (CIS) precluding curative chemoradiotherapy.
• Evidence of distant metastatic disease on a CT or FDG PET/CT chest/abdomen/pelvis performed within 28 days prior to study entry. Up to 3 metastatic lymphnodes in the pelvis (below the common iliac arteries) are allowed, if these can be incorporated in the radiotherapy field.
• Prior pelvic lymph-adenectomy
• Prior pelvic radiotherapy
• Has had prior intravenous chemotherapy, targeted small molecule therapy, or radiation therapy for treatment of bladder cancer. Prior intravesical use of BCG and MMC is permissible.
• Unsuitable for concurrent MMC / capecitabine based ChRT based on pre-existing medical conditions.
• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment.
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy over 10mg daily prednisone (or equivalent) or any other form of immunosuppressive therapy within 14 days prior to registering the patient. Patients with adrenal insufficiency receiving replacement dose steroids are allowed on the trial.
• Has a known history of active TB (Bacillus Tuberculosis)
• Hypersensitivity to nivolumab and/or ipilimumab or any of its excipients.
• Prior or concurrent known additional malignancy of any site unless disease free for 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, Stage T1a well differentiated prostatic carcinoma in men (Gleason = 3+3, PSA \<5)
• Has any history of active autoimmune disease, Stevens-Johnson syndrome or Guillain-Barre. Exceptions to this are:
• Patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone

Sponsors & Collaborators

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): lead
• Bristol-Myers Squibb: collaborator

Study Sites (3)

Amsterdam UMC, VUmc

Amsterdam, North Holland, 1081 HV, Netherlands

RECRUITING

Amsterdam UMC, AMC

Amsterdam, North Holland, 1105 AZ, Netherlands

RECRUITING

LUMC

Leiden, South Holland, Netherlands

RECRUITING

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Interventions

Nivolumab; Mitomycin; Capecitabine; Ipilimumab

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Mitomycins; Indolequinones; Quinones; Organic Chemicals; Azirines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Officials

• Adriaan D. Bins, MD PhD

  Amsterdam UMC, AMC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Adriaan D. Bins, MD PhD

CONTACT

0205662339; a.d.bins@amc.uva.nl

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Patients will be treated with radiation therapy over 4 weeks and receive MMC IV on day1 of radiation therapy and capecitabine on each day of radiation therapy as radiosensitizers. Phase-1b: enrollment of maximum of 30 patients with a maximum of 10 patients per treatment regimen, in order to determine optimal regimen based on the occurrence of dose limiting toxicities (DLT). * Regimen-A: immunotherapy (w1-12) consists of nivolumab 480mg (fixed dose), on day(d)1, d29 and d57. * Regimen-B: immunotherapy (w1-12) consists of ipilimumab 1 mg/kg together with Nivolumab 3mg/kg on d1, d22, d43 and d65. * Regimen-C: immunotherapy (w1-12) consists of ipilimumab 3 mg/kg and nivolumab 1 mg/kg on d1, d22, d43 and d65. All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52. Phase-2: enrollment of an additional 20 subjects at the regimen determined to be optimal in the phase-1b part.

Study Record Dates

• First Submitted: February 13, 2019
• First Posted: February 18, 2019
• Study Start: January 7, 2019
• Primary Completion: July 1, 2024
• Study Completion (Estimated): July 1, 2026
• Last Updated: August 12, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

NL (3)